Reviewing NeurAxis (NASDAQ:NRXS) & NovoCure (NASDAQ:NVCR)

NovoCure (NASDAQ:NVCR) and NeurAxis (NASDAQ:NRXS) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, profitability, earnings, dividends, valuation, analyst recommendations and institutional ownership.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for NovoCure and NeurAxis, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NovoCure	1	4	2	0	2.14
NeurAxis	0	1	1	0	2.50

NovoCure presently has a consensus target price of $21.20, indicating a potential upside of 53.18%. NeurAxis has a consensus target price of $13.00, indicating a potential upside of 99.08%. Given NeurAxis’ stronger consensus rating and higher possible upside, analysts clearly believe NeurAxis is more favorable than NovoCure.

Risk & Volatility

NovoCure has a beta of 0.99, suggesting that its share price is 1% less volatile than the S&P 500. Comparatively, NeurAxis has a beta of 1.38, suggesting that its share price is 38% more volatile than the S&P 500.

Institutional and Insider Ownership

84.6% of NovoCure shares are owned by institutional investors. Comparatively, 11.8% of NeurAxis shares are owned by institutional investors. 6.6% of NovoCure shares are owned by insiders. Comparatively, 21.1% of NeurAxis shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Profitability

This table compares NovoCure and NeurAxis’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
NovoCure	-21.25%	-44.00%	-15.85%
NeurAxis	-492.76%	N/A	-641.25%

Earnings and Valuation

This table compares NovoCure and NeurAxis”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NovoCure	$655.35 million	2.46	-$136.23 million	($1.30)	-10.65
NeurAxis	$5.32 million	15.43	-$14.63 million	($0.78)	-8.37

NeurAxis has lower revenue, but higher earnings than NovoCure. NovoCure is trading at a lower price-to-earnings ratio than NeurAxis, indicating that it is currently the more affordable of the two stocks.

Summary

NeurAxis beats NovoCure on 8 of the 13 factors compared between the two stocks.

About NovoCure

NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, Japan, Greater China, and internationally. The company’s TTFields devices include Optune Gio and Optune Lua. It also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Saint Helier, Jersey.

About NeurAxis

NeurAxis, Inc., a medical technology company, focuses on developing neuromodulation therapies to address chronic and debilitating conditions in children and adults in the United States. It offers IB-Stim, a percutaneous electrical nerve field stimulation system intended to be used in patients 11-18 years of age with functional abdominal pain associated with irritable bowel syndrome. The company sells its products to healthcare companies, including hospitals and clinics. The company was formerly known as Innovative Health Solutions, Inc. and changed its name to NeurAxis, Inc. in March 2022. The company was founded in 2011 and is headquartered in Carmel, Indiana.